Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade A 14.71 6.36% 0.88
XENE closed up 6.36 percent on Tuesday, December 10, 2019, on 2.49 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
See historical XENE trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 6.36%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 6.36%
Calm After Storm Range Contraction 6.36%
Outside Day Range Expansion 6.36%
Wide Bands Range Expansion 6.36%
Overbought Stochastic Strength 6.36%
Older signals for XENE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Chemistry Biopharmaceutical Pain Chemical Compounds Organic Compounds Gene Therapy Osteoarthritis Acne Cardiovascular Disease Analgesics Genentech Treatment Of Osteoarthritis Indoles Lipoprotein Lipase Deficiency Alipogene Tiparvovec Glybera Postherpetic Neuralgia

Is XENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.95
52 Week Low 5.41
Average Volume 109,274
200-Day Moving Average 9.55
50-Day Moving Average 9.71
20-Day Moving Average 11.17
10-Day Moving Average 13.16
Average True Range 0.86
ADX 41.07
+DI 36.12
-DI 10.05
Chandelier Exit (Long, 3 ATRs ) 12.38
Chandelier Exit (Short, 3 ATRs ) 11.19
Upper Bollinger Band 15.49
Lower Bollinger Band 6.85
Percent B (%b) 0.91
BandWidth 77.39
MACD Line 1.41
MACD Signal Line 1.03
MACD Histogram 0.3769
Fundamentals Value
Market Cap 264.73 Million
Num Shares 18 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -8.86
Price-to-Sales 65.85
Price-to-Book 1.07
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.44
Resistance 3 (R3) 16.32 15.64 16.15
Resistance 2 (R2) 15.64 15.20 15.69 16.05
Resistance 1 (R1) 15.17 14.93 15.41 15.29 15.96
Pivot Point 14.49 14.49 14.60 14.54 14.49
Support 1 (S1) 14.02 14.05 14.26 14.14 13.46
Support 2 (S2) 13.34 13.78 13.39 13.37
Support 3 (S3) 12.87 13.34 13.27
Support 4 (S4) 12.99